Your browser doesn't support javascript.
loading
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.
Dietz, Julia; Spengler, Ulrich; Müllhaupt, Beat; Schulze Zur Wiesch, Julian; Piecha, Felix; Mauss, Stefan; Seegers, Barbara; Hinrichsen, Holger; Antoni, Christoph; Wietzke-Braun, Perdita; Peiffer, Kai-Henrik; Berger, Annemarie; Matschenz, Katrin; Buggisch, Peter; Backhus, Johanna; Zizer, Eugen; Boettler, Tobias; Neumann-Haefelin, Christoph; Semela, David; Stauber, Rudolf; Berg, Thomas; Berg, Christoph; Zeuzem, Stefan; Vermehren, Johannes; Sarrazin, Christoph.
Afiliación
  • Dietz J; Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt, and German Center for Infection Research (DZIF), External Partner Site, Frankfurt, Germany.
  • Spengler U; Department of Internal Medicine I, University of Bonn, Bonn, and German Center for Infection Research (DZIF), Partner Site, Cologne-Bonn, Germany.
  • Müllhaupt B; Swiss Hepato-Pancreato-Biliary Center and Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.
  • Schulze Zur Wiesch J; I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, and German Center for Infection Research (DZIF), Partner Site, Hamburg-Lübeck-Borstel-Riems, Germany.
  • Piecha F; I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, and German Center for Infection Research (DZIF), Partner Site, Hamburg-Lübeck-Borstel-Riems, Germany.
  • Mauss S; Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.
  • Seegers B; Gastroenterologisch-Hepatologisches Zentrum Kiel, Kiel, Germany.
  • Hinrichsen H; Gastroenterologisch-Hepatologisches Zentrum Kiel, Kiel, Germany.
  • Antoni C; Department of Internal Medicine II, University Hospital Mannheim, Mannheim, Germany.
  • Wietzke-Braun P; Medical Department I, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Peiffer KH; Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt, and German Center for Infection Research (DZIF), External Partner Site, Frankfurt, Germany.
  • Berger A; Institute for Medical Virology, University Hospital Frankfurt, Frankfurt, Germany.
  • Matschenz K; Institute for Interdisciplinary Medicine IFI, Hamburg, Germany.
  • Buggisch P; Institute for Interdisciplinary Medicine IFI, Hamburg, Germany.
  • Backhus J; Department of Internal Medicine I, Ulm University, Ulm, Germany.
  • Zizer E; Department of Internal Medicine I, Ulm University, Ulm, Germany.
  • Boettler T; Department of Medicine II, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Neumann-Haefelin C; Department of Medicine II, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Semela D; Division of Gastroenterology and Hepatology, Kantonsspital St Gallen, St Gallen, Switzerland.
  • Stauber R; Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Berg T; Department of Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany.
  • Berg C; Department of Internal Medicine I, University of Tübingen, Tübingen, Germany.
  • Zeuzem S; Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt, and German Center for Infection Research (DZIF), External Partner Site, Frankfurt, Germany.
  • Vermehren J; Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt, and German Center for Infection Research (DZIF), External Partner Site, Frankfurt, Germany.
  • Sarrazin C; Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt, and German Center for Infection Research (DZIF), External Partner Site, Frankfurt, Germany; Medizinische Klinik 2, St Josefs-Hospital, Wiesbaden, Germany. Electronic address: sarrazin@em.uni-frankfurt.de.
Clin Gastroenterol Hepatol ; 19(1): 195-198.e2, 2021 01.
Article en En | MEDLINE | ID: mdl-31706062
Hepatitis C virus infection is causing chronic liver disease, cirrhosis, and hepatocellular carcinoma. By combining direct-acting antivirals (DAAs), high sustained virologic response rates (SVRs) can be achieved. Resistance-associated substitutions (RASs) are commonly observed after DAA failure, and especially nonstructural protein 5A (NS5A) RASs may impact retreatment options.1-3 Data on retreatment of DAA failure patients using first-generation DAAs are limited.4-7 Recently, a second-generation protease- and NS5A-inhibitor plus sofosbuvir (voxilaprevir/velpatasvir/sofosbuvir [VOX/VEL/SOF]) was approved for retreatment after DAA failure.8 However, this and other second-generation regimens are not available in many resource-limited countries or are not reimbursed by regular insurance, and recommendations regarding the selection of retreatment regimens using first-generation DAAs are very important. This study aimed to analyze patients who were re-treated with first-generation DAAs after failure of a DAA combination therapy.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hepatitis C / Hepatitis C Crónica / Neoplasias Hepáticas Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Clin Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hepatitis C / Hepatitis C Crónica / Neoplasias Hepáticas Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Clin Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos